Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Olivia Newton-John Cancer Research Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04969887CT.gov Combination Immunotherapy in Rare Cancers Under InvesTigation | — | Active Not Recruiting | — | — | — |
NCT04079712CT.gov Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors | — | Active Not Recruiting | — | — | — |
NCT02923934CT.gov A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | Olivia Newton-John Cancer Research Institute | P2 | B · 57 |
| Irinotecan | First Affiliated Hospital Xi'an Jiaotong University | P4 | BB |
| Fluorouracilum | ITM Solucin GmbH | P3 | BB |
| Cabozantinib | Fox Chase Cancer Center | P3 | BB |
| Oxodotreotide | Fundación de investigación HM | P3 | BB |
| Surufatinib | Shanghai Changzheng Hospital | P3 | BB |
| Everolimus | Exelixis | P3 | BB |
| Carboplatin | First Affiliated Hospital Xi'an Jiaotong University | P4 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | B |
+42 more in the Neuroendocrine Neoplasm cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-neuroendocrine-neoplasm-76273
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →